FDA Accepts Supplemental NDA for Sotagliflozin by Lexicon Pharmaceuticals
The FDA has accepted the supplemental NDA for sotagliflozin (NDA216203) submitted by Lexicon Pharmaceuticals.
Company
Pharmaceutical intelligence for Lexicon Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.